AR048327A1 - Derivados de imidazol - Google Patents
Derivados de imidazolInfo
- Publication number
- AR048327A1 AR048327A1 ARP050101136A ARP050101136A AR048327A1 AR 048327 A1 AR048327 A1 AR 048327A1 AR P050101136 A ARP050101136 A AR P050101136A AR P050101136 A ARP050101136 A AR P050101136A AR 048327 A1 AR048327 A1 AR 048327A1
- Authority
- AR
- Argentina
- Prior art keywords
- mean
- hal
- independently
- cooa
- derivatives
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 abstract 1
- -1 COOA Chemical group 0.000 abstract 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000002460 imidazoles Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 abstract 1
- 102000009929 raf Kinases Human genes 0.000 abstract 1
- 108010077182 raf Kinases Proteins 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
Abstract
Derivados de imidazol, así como sus derivados, solvatos, sales y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones, son inhibidores de las tirosina quinasas, en especial de la TIE-2, y de las Raf-quinasas, y se pueden utilizar, por ejemplo, para el tratamiento de tumores. Reivindicacion 1: Compuestos de la formula (1) en donde R1, R2, R3, R4, R5 significan cada uno, de modo independiente entre sí, H, A, OH, OA, alquenilo, alquinilo, NO2, NH2, NHA, NA2, Hal, CN, COOH, COOA, OHet, -O-alquilen-Het, -O-alquilen-NR10R11 o CONR10R11, dos radicales adyacentes seleccionados de R1, R2, R3, R4, R5 también significan, -O-CH2-CH2-, -O-CH2-O- u -O-CH2-CH2-O-, R6, R7 significan cada uno, de modo independiente entre sí, H, A, Hal, OH, OA o CN; R8 significa CN, COOH, COOA, CONH2, CONHA o CONA2, R9 significa H o A; R10, R11 significan cada uno, de modo independiente entre sí, H o A; Het significa un heterociclo monocíclico o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede estar insustituido o mono, bi o trisustituido con Hal, A, OA, COOA, CN y/o el O del carbonilo (=O), A significa alquilo C1-10, en donde también 1-7 átomos de H pueden estar reemplazados por F y/o Cl; X, X' significan cada uno, de modo independienteentre sí, NH o están ausentes, Hal significa F, Cl, Br o I; así como sus derivados, solvatos, sales y estereoisomeros deutilidad farmacéutica, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004015099A DE102004015099A1 (de) | 2004-03-29 | 2004-03-29 | Imidazolderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048327A1 true AR048327A1 (es) | 2006-04-19 |
Family
ID=34981611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101136A AR048327A1 (es) | 2004-03-29 | 2005-03-23 | Derivados de imidazol |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070225347A1 (es) |
| EP (1) | EP1761503A2 (es) |
| JP (1) | JP2007530609A (es) |
| KR (1) | KR20060132965A (es) |
| CN (1) | CN1938282A (es) |
| AR (1) | AR048327A1 (es) |
| AU (1) | AU2005231907A1 (es) |
| BR (1) | BRPI0508881A (es) |
| CA (1) | CA2561585A1 (es) |
| DE (1) | DE102004015099A1 (es) |
| RU (1) | RU2006138150A (es) |
| WO (1) | WO2005097755A2 (es) |
| ZA (1) | ZA200608998B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1858877T3 (pl) | 2005-01-14 | 2014-08-29 | Gilead Connecticut Inc | 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy |
| US7777040B2 (en) | 2005-05-03 | 2010-08-17 | Cgi Pharmaceuticals, Inc. | Certain substituted ureas, as modulators of kinase activity |
| EP2004631A1 (en) * | 2006-04-12 | 2008-12-24 | Merck Patent GmbH | N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| CN103910714A (zh) * | 2013-01-09 | 2014-07-09 | 天津泰瑞倍药研科技有限公司 | 氟代环丁烷基咪唑类化合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| JP2006515828A (ja) * | 2001-09-27 | 2006-06-08 | スミスクライン・ビーチャム・コーポレイション | 化学化合物 |
-
2004
- 2004-03-29 DE DE102004015099A patent/DE102004015099A1/de not_active Withdrawn
-
2005
- 2005-03-15 BR BRPI0508881-0A patent/BRPI0508881A/pt not_active IP Right Cessation
- 2005-03-15 US US10/593,295 patent/US20070225347A1/en not_active Abandoned
- 2005-03-15 WO PCT/EP2005/002746 patent/WO2005097755A2/de active Application Filing
- 2005-03-15 EP EP05716076A patent/EP1761503A2/de not_active Withdrawn
- 2005-03-15 KR KR1020067020089A patent/KR20060132965A/ko not_active Application Discontinuation
- 2005-03-15 AU AU2005231907A patent/AU2005231907A1/en not_active Abandoned
- 2005-03-15 CN CNA200580010619XA patent/CN1938282A/zh active Pending
- 2005-03-15 CA CA002561585A patent/CA2561585A1/en not_active Abandoned
- 2005-03-15 JP JP2007505422A patent/JP2007530609A/ja active Pending
- 2005-03-15 RU RU2006138150/04A patent/RU2006138150A/ru not_active Application Discontinuation
- 2005-03-23 AR ARP050101136A patent/AR048327A1/es unknown
-
2006
- 2006-10-30 ZA ZA200608998A patent/ZA200608998B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005097755A2 (de) | 2005-10-20 |
| JP2007530609A (ja) | 2007-11-01 |
| EP1761503A2 (de) | 2007-03-14 |
| US20070225347A1 (en) | 2007-09-27 |
| BRPI0508881A (pt) | 2007-09-11 |
| ZA200608998B (en) | 2008-07-30 |
| RU2006138150A (ru) | 2008-05-10 |
| AU2005231907A1 (en) | 2005-10-20 |
| CN1938282A (zh) | 2007-03-28 |
| KR20060132965A (ko) | 2006-12-22 |
| DE102004015099A1 (de) | 2005-10-20 |
| CA2561585A1 (en) | 2005-10-20 |
| WO2005097755A3 (de) | 2006-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051623A1 (es) | Derivados de piridopirimidinona | |
| AR046929A1 (es) | Piridopirimidinonas | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| AR053569A1 (es) | Derivados de pirazol | |
| ECSP109953A (es) | Derivados de piridazinona | |
| CY1124519T1 (el) | ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΚΑΙ ΦΑΡΜΑΚΟΤΕΧΝΙΚΕΣ ΜΟΡΦΕΣ ΤΟΥ (S)-4-(8-ΑΜΙΝΟ-3-(1-(ΒΟΥΤ-2-ΥΝΟΫΛΟ)ΠΥΡΡΟΛΙΔΙΝ-2-ΥΛΟ) ΙΜΙΔΑΖΟ[1,5-α|ΠΥΡΑΖΙΝ-1-ΥΛΟ)-Ν-(ΠΥΡΙΔΙΝ-2-ΥΛΟ) ΒΕΝΖΑΜΙΔΙΟΥ | |
| AR046748A1 (es) | Derivados de amina que inhiben,regulan,y/o modulan tirosinaquinasas,composiciones farmaceuticas que los contienen,procedimientos de preparacion y compuestos intermediarios | |
| AR048327A1 (es) | Derivados de imidazol | |
| ECSP10010361A (es) | Derivados de piridazinona | |
| NI200700313A (es) | Aminopirimidinas como moduladores de la cinasa . | |
| AR056691A1 (es) | Derivados pirrolopirimidina como inhibidores de syk | |
| SV2010003482A (es) | Imidazoles fusionados para el tratamiento del cancer | |
| CO6361936A2 (es) | Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa | |
| BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
| CL2012000059A1 (es) | Compuestos derivados de pirazolo[1,5-a]pirimidina; proceso de preparacion; composicion farmaceutica que los comprende; y su uso como inhbidores de trk-quinasa para el tratamiento de enfermedades o trastornos tales como dolor, cancer, inflamacion; entre otras. | |
| NI200700316A (es) | Aminopirimidinas como moduladores de la cinasa | |
| CO6561821A2 (es) | Compuesto n-(1h-indazol-4-il)imidazol[1.2-a]piridin -3-carboxamida sustituidos como inhibidores de cfms | |
| AR068075A1 (es) | Compuestos de piperazina con accion herbicida. proceso de preparacion | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| UY32585A (es) | Nuevos derivados del indazol utiles como inhibidores de la familia fosfoinositida 3´oh quinasa | |
| UY31126A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
| AR057322A1 (es) | Quinazolinonas, procesos de obtencion y composiciones farmaceuticas | |
| PE20210373A1 (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos | |
| AR052302A1 (es) | Derivados de sulfonamidas, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| CR9652A (es) | Moduladores de alquilquinolina y alquilquinazolina cinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |